Across TCGA pan-cancer cohorts, NAP1L1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NAP1L1 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NAP1L1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAP1L1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where NAP1L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.280	0.739	.001	52	view →
HNSC	DFS	Median	III,IV	1.000	0.903	.004	7	view →
GBM	DFS	Tertile	All	0.659	0.916	.004	5	view →
LSCC	DFS	Tertile	All	0.987	0.896	.021	4	view →
LUAD	DFS	Median	III,IV	0.980	0.539	.001	3	view →
PDAC	DFS	Tertile	All	0.911	0.750	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: NAP1L1 tumor-vs-normal RNA expression · all NAP1L1 data types